Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Rethinking OAB treatment and dementia risk: A large study of over 830,000 adults found that β3 adrenergic agonists — often considered the "safer" option for overactive bladder — don't actually carry a lower dementia risk than anticholinergic medications. In fact, high-risk anticholinergics were associated with a slightly lower dementia hazard than β3 agonists. Short-term cognitive side effects from anticholinergics remain, but they resolve upon stopping the medication.
Rethinking the "safer" OAB drug for dementia risk
For years, β3 adrenergic agonists have been positioned as the brain-friendlier alternative to anticholinergics for treating overactive bladder (OAB) — but a large new study challenges that assumption. Researchers from University Hospitals Cleveland Medical Center analyzed electronic health records of over 830,000 adults (ages 40–90) newly treated for OAB between 2012 and 2025, and found that β3 agonists did not confer a lower dementia risk compared to anticholinergic medications.
After statistical adjustment, high-risk anticholinergics were actually associated with a lower hazard of dementia than β3 agonists. There was no meaningful difference in dementia risk between low-risk anticholinergics and β3 agonists, and longer anticholinergic use did not increase dementia risk.
By the Numbers
Why it matters: Clinicians have increasingly steered OAB patients toward β3 agonists to sidestep perceived dementia risk from anticholinergics — but this study suggests that switch may not be warranted. Short-term cognitive side effects from anticholinergics are real but reversible, and patients can be reassured that a medication trial won't cause lasting harm.